No Cash? No Problem
Diagnostics Firms Flexible in Forming Biotech RxDx Deals
Melanoma drug Zelboraf (vemurafenib, Daiichi Sankyo Co. Ltd. and Roche AG) and lung cancer drug Xalkori (crizotinib, Pfizer Inc.) proved incorporating a companion diagnostic early in clinical development can save time and money: Both drugs advanced from Phase I to FDA approval in five years. (See BioWorld Insight, Sept. 6, 2011.)
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.